ENA Respiratory
ENA Respiratory is a clinical-stage pharmaceutical company tackling respiratory viral infections through the development of host defense enhancers which locally prime and boost the body's natural first line of defense against invading pathogens. Being virus-agnostic, ENA's approach offers a solution to protect against common and emerging respiratory viruses for which vaccines or direct-acting antivirals have limitations or do not exist.
Leadership & Board
- Current Number of Employees
- 10
- Current LinkedIn Followers
- 1,518
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $22M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $22M
- Latest Funding Round
- Series B
- Post-Money Valuation
- ―
Employee Trend
ENA Respiratory had 10 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
ENA Respiratory had 1,518 followers as of October 12, 2026. The number of followers increased by 0 (0.00%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 22, 2025 | Series B | $22.40M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Brandon Capital | Series B |
| Uniseed | Series B |
| Gates Foundation | Series B |
| Flu Lab | Series B |
| Stoic Venture Capital | Series B |
Similar Companies
A snapshot of private companies similar to ENA Respiratory, helping you discover and navigate related company profiles.
Related News and Analysis
